Cellect Biotechnology Ltd. (APOP): Price and Financial Metrics

Cellect Biotechnology Ltd. (APOP)

Today's Latest Price: $3.13 USD

0.07 (-2.19%)

Updated Jul 10 4:00pm

Add APOP to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

APOP Daily Price Range
APOP 52-Week Price Range

APOP Stock Price Chart Technical Analysis Charts

APOP Price/Volume Stats

Current price $3.13 52-week high $6.89
Prev. close $3.20 52-week low $0.40
Day low $3.13 Volume 47,060
Day high $3.25 Avg. volume 1,075,319
50-day MA $3.04 Dividend yield N/A
200-day MA $2.51 Market Cap 7.01M

Cellect Biotechnology Ltd. (APOP) Company Bio

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is based in Kfar Saba, Israel.

APOP Latest News Stream

Event/TimeNews Detail
Loading, please wait...

APOP Latest Social Stream

Loading social stream, please wait...

View Full APOP Social Stream

Latest APOP News From Around the Web

Below are the latest news stories about Cellect Biotechnology Ltd that investors may wish to consider to help them evaluate APOP as an investment opportunity.

Cellect Biotechnology Reports First Quarter 2020 Financial and Operating Results; Continues to Demonstrate Significant Progress Despite Adjusted Operations Due to COVID-19

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the first quarter ended March 31, 2020 and provided an update on recent operating developments, including the status of the previously announced LOIs with Canndoc Ltd, a wholly owned subsidiary of publicly-traded Intercure Ltd. (TASE: INCR).

Yahoo | May 21, 2020

Cellect Biotechnology's ApoGraft™ to Empower Cellular Treatment of COVID-19 Related Pulmonary Diseases

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that it has signed a development agreement with an international consortium to examine the therapeutic effects of ApoGraft treated stem cells on the reduction of pulmonary manifestations caused by COVID-19. The Company has completed the technology and material transfer and the pre-clinical studies are progressing. The development agreement includes a commercial component, enabling the Company to receive royalties upon the commercialization of the intended product. The Company did not disclose the terms of the agreement, nor any members of the international consortium.

Yahoo | May 18, 2020

Company News for May 12, 2020

Companies In The News Are:

Yahoo | May 12, 2020

Cellect Biotechnology Announces Exercise of Warrants for Cash Proceeds of Approximately $1.5 Million

Cellect Biotechnology Ltd. (APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced the agreement by several investors to exercise certain warrants issued in February 2019 to purchase up to an aggregate of 534,160,000 ordinary shares represented by 534,160 American Depositary Shares (ADSs) having an original exercise price of $7.50 per ADS,  at a reduced exercise price of $2.75 per ADSs. Simultaneously with entry into these agreements the Company determined to lower the exercise price of all outstanding warrants issued in February 2019 with an original exercise price of $7.50 to $2.75 per share. The gross proceeds to Cellect from the exercise of the warrants are expected to be approximately $1.5 million, prior to deducting plac...

Yahoo | May 12, 2020

Why Israeli Stem Cell Therapy Company Cellect Biotech Is Rallying

Shares of nano-cap stem cell therapy company Cellect Biotechnology Ltd – ADR (NASDAQ: APOP ) were advancing strongly Monday. Why Cellect Bio Is Rallying The Tel Aviv, Israel-based company announced the publication in the peer-reviewed medical journal Bone Marrow Transplantation of an article entitled "Ex-vivo FAS-ligand to Improve Allograft Safety," which highlighted pre-clinical research findings that engraftment is robust following transplantation of treated graft. The graft retained its immune reconstitution and anti-leukemic effects, the company said. Cellect said it has initiated a Phase 1/2 study in adults undergoing stem cell transplant for the treatment of hematological malignancies. … Full story available on Benzinga.com

Benzinga | May 11, 2020

Read More 'APOP' Stories Here

APOP Price Returns

1-mo 2.62%
3-mo N/A
6-mo -0.32%
1-year 20.38%
3-year -92.08%
5-year N/A
YTD 41.01%
2019 -78.86%
2018 -70.00%
2017 126.54%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8728 seconds.